Protective role of adiponectin in cardiovascular disease

Current Medicinal Chemistry

Volumn 19, Issue 32, 2012, Pages 5459-5466

  Shibata, R ^a   Murohara, T ^a   Ouchi, N ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Atherosclerosis; Coronary artery disease; Inflammation; Ischemic heart disease

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; DOXORUBICIN; FENOFIBRATE; PIOGLITAZONE; TELMISARTAN;

ADIPOCYTE; ADIPOSE TISSUE; APOPTOSIS; ATHEROSCLEROSIS; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL COMPONENT; CORONARY ARTERY DISEASE; DOWN REGULATION; ENDOTHELIUM CELL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; REVIEW; SMOOTH MUSCLE FIBER;

ADIPONECTIN; ANIMALS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; HUMANS; MYOCARDIUM; RECEPTORS, ADIPONECTIN;

EID: 84870401115     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803833164     Document Type: Review

References (121)

1. Ouchi, N.; Parker, J. L.; Lugus, J. J.; Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol., 2011, 11, 85-97.
2. Matsuzawa, Y. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med., 2006, 3, 35-42.
3. Ouchi, N.; Higuchi, A.; Ohashi, K.; Oshima, Y.; Gokce, N.; Shibata, R.; Akasaki, Y.; Shimono, A.; Walsh, K. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science, 2010, 329, 454-7.
4. Lago, F.; Dieguez, C.; Gomez-Reino, J.; Gualillo, O. Adipokines as emerging mediators of immune response and inflammation. Nat. Clin. Pract. Rheumatol., 2007, 3, 716-24.
5. Enomoto, T.; Ohashi, K.; Shibata, R.; Higuchi, A.; Maruyama, S.; Izumiya, Y.; Walsh, K.; Murohara, T.; Ouchi, N. Adipolin/C1qdc2/CTRP12 Protein Functions as an Adipokine That Improves Glucose Metabolism. J. Biol. Chem., 2011, 286, 34552-8.
6. Shibata, R.; Ouchi, N.; Murohara, T. Adiponectin and cardiovascular disease. Circ. J., 2009, 73, 608-14.
7. Maeda, K.; Okubo, K.; Shimomura, I.; Funahashi, T.; Matsuzawa, Y.; Matsubara, K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun., 1996, 221, 286-9.
8. Scherer, P. E.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish, H. F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem., 1995, 270, 26746-9.
9. Hu, E.; Liang, P.; Spiegelman, B. M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem., 1996, 271, 10697-703.
10. Kishida, K.; Nagaretani, H.; Kondo, H.; Kobayashi, H.; Tanaka, S.; Maeda, N.; Nagasawa, A.; Hibuse, T.; Ohashi, K.; Kumada, M.; Nishizawa, H.; Okamoto, Y.; Ouchi, N.; Maeda, K.; Kihara, S.; Funahashi, T.; Matsuzawa, Y. Disturbed secretion of mutant adiponectin associated with the metabolic syndrome. Biochem. Biophys. Res. Commun., 2003, 306, 286-92.
11. Pajvani, U. B.; Du, X.; Combs, T. P.; Berg, A. H.; Rajala, M. W.; Schulthess, T.; Engel, J.; Brownlee, M.; Scherer, P. E. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J. Biol. Chem., 2003, 278, 9073-85.
12. Ryo, M.; Nakamura, T.; Kihara, S.; Kumada, M.; Shibazaki, S.; Takahashi, M.; Nagai, M.; Matsuzawa, Y.; Funahashi, T. Adiponectin as a biomarker of the metabolic syndrome. Circ. J., 2004, 68, 975-81.
13. Arita, Y.; Kihara, S.; Ouchi, N.; Takahashi, M.; Maeda, K.; Miyagawa, J.; Hotta, K.; Shimomura, I.; Nakamura, T.; Miyaoka, K.; Kuriyama, H.; Nishida, M.; Yamashita, S.; Okubo, K.; Matsubara, K.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun., 1999, 257, 79-83.
14. Cnop, M.; Havel, P. J.; Utzschneider, K. M.; Carr, D. B.; Sinha, M. K.; Boyko, E. J.; Retzlaff, B. M.; Knopp, R. H.; Brunzell, J. D.; Kahn, S. E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 2003, 46, 459-69.
15. Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; Maeda, K.; Nishida, M.; Kihara, S.; Sakai, N.; Nakajima, T.; Hasegawa, K.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Hanafusa, T.; Matsuzawa, Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1595-9.
16. Lindsay, R. S.; Funahashi, T.; Hanson, R. L.; Matsuzawa, Y.; Tanaka, S.; Tataranni, P. A.; Knowler, W. C.; Krakoff, J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet, 2002, 360, 57-8.
17. Spranger, J.; Kroke, A.; Mohlig, M.; Bergmann, M. M.; Ristow, M.; Boeing, H.; Pfeiffer, A. F. Adiponectin and protection against type 2 diabetes mellitus. Lancet, 2003, 361, 226-8.
18. Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y.; Walsh, K. Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol., 2003, 14, 561-6.
19. Savopoulos, C.; Michalakis, K.; Apostolopoulou, M.; Miras, A.; Hatzitolios, A. Adipokines and stroke: a review of the literature. Maturitas, 2011, 70, 322-7.
20. O'Leary, D. H.; Polak, J. F.; Kronmal, R. A.; Manolio, T. A.; Burke, G. L.; Wolfson, S. K., Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med., 1999, 340, 14-22.
21. Nilsson, P. M.; Engstrom, G.; Hedblad, B.; Frystyk, J.; Persson, M. M.; Berglund, G.; Flyvbjerg, A. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2758-62.
22. Lo, J.; Dolan, S. E.; Kanter, J. R.; Hemphill, L. C.; Connelly, J. M.; Lees, R. S.; Grinspoon, S. K. Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women. J. Clin. Endocrinol. Metab., 2006, 91, 1677-82.
23. Hayashi, M.; Shibata, R.; Takahashi, H.; Ishii, H.; Aoyama, T.; Kasuga, H.; Yamada, S.; Ohashi, K.; Maruyama, S.; Matsuo, S.; Ouchi, N.; Murohara, T.; Toriyama, T. Association of adiponectin with carotid arteriosclerosis in predialysis chronic kidney disease. Am. J. Nephrol., 2011, 34, 249-55.
24. Juonala, M.; Saarikoski, L. A.; Viikari, J. S.; Oikonen, M.; Lehtimaki, T.; Lyytikainen, L. P.; Huupponen, R.; Magnussen, C. G.; Koskinen, J.; Laitinen, T.; Taittonen, L.; Kahonen, M.; Kivimaki, M.; Raitakari, O. T. A longitudinal analysis on associations of adiponectin levels with metabolic syndrome and carotid artery intima-media thickness. The Cardiovascular Risk in Young Finns Study. Atherosclerosis, 2011, 217, 234-9.
25. Ouchi, N.; Kihara, S.; Arita, Y.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 1999, 100, 2473-6.
26. Kumada, M.; Kihara, S.; Sumitsuji, S.; Kawamoto, T.; Matsumoto, S.; Ouchi, N.; Arita, Y.; Okamoto, Y.; Shimomura, I.; Hiraoka, H.; Nakamura, T.; Funahashi, T.; Matsuzawa, Y. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 85-9.
27. Pischon, T.; Girman, C. J.; Hotamisligil, G. S.; Rifai, N.; Hu, F. B.; Rimm, E. B. Plasma adiponectin levels and risk of myocardial infarction in men. Jama, 2004, 291, 1730-7.
28. Schulze, M. B.; Shai, I.; Rimm, E. B.; Li, T.; Rifai, N.; Hu, F. B. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes, 2005, 54, 534-9.
29. Zoccali, C.; Mallamaci, F.; Tripepi, G.; Benedetto, F. A.; Cutrupi, S.; Parlongo, S.; Malatino, L. S.; Bonanno, G.; Seminara, G.; Rapisarda, F.; Fatuzzo, P.; Buemi, M.; Nicocia, G.; Tanaka, S.; Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J. Am. Soc. Nephrol., 2002, 13, 134-41.
30. Ai, M.; Otokozawa, S.; Asztalos, B. F.; White, C. C.; Cupples, L. A.; Nakajima, K.; Lamon-Fava, S.; Wilson, P. W.; Matsuzawa, Y.; Schaefer, E. J. Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis, 2011, 217, 543-8.
31. Otsuka, F.; Sugiyama, S.; Kojima, S.; Maruyoshi, H.; Funahashi, T.; Matsui, K.; Sakamoto, T.; Yoshimura, M.; Kimura, K.; Umemura, S.; Ogawa, H. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J. Am. Coll. Cardiol., 2006, 48, 1155-62.
32. Cote, M.; Cartier, A.; Reuwer, A. Q.; Arsenault, B. J.; Lemieux, I.; Despres, J. P.; Wareham, N. J.; Kastelein, J. J.; Boekholdt, S. M.; Khaw, K. T. Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study). Am. J. Cardiol., 2011, 108, 367-73.
33. Lindsay, R. S.; Resnick, H. E.; Zhu, J.; Tun, M. L.; Howard, B. V.; Zhang, Y.; Yeh, J.; Best, L. G. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol., 2005, 25, e15-6.
34. Lawlor, D. A.; Davey Smith, G.; Ebrahim, S.; Thompson, C.; Sattar, N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J. Clin. Endocrinol. Metab., 2005, 90, 5677-83.
35. Sattar, N.; Wannamethee, G.; Sarwar, N.; Tchernova, J.; Cherry, L.; Wallace, A. M.; Danesh, J.; Whincup, P. H. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation, 2006, 114, 623-9.
36. Okamoto, Y.; Kihara, S.; Ouchi, N.; Nishida, M.; Arita, Y.; Kumada, M.; Ohashi, K.; Sakai, N.; Shimomura, I.; Kobayashi, H.; Terasaka, N.; Inaba, T.; Funahashi, T.; Matsuzawa, Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2002, 106, 2767-70.
37. Okamoto, Y.; Folco, E. J.; Minami, M.; Wara, A. K.; Feinberg, M. W.; Sukhova, G. K.; Colvin, R. A.; Kihara, S.; Funahashi, T.; Luster, A. D.; Libby, P. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ. Res., 2008, 102, 218-25.
38. Matsuda, M.; Shimomura, I.; Sata, M.; Arita, Y.; Nishida, M.; Maeda, N.; Kumada, M.; Okamoto, Y.; Nagaretani, H.; Nishizawa, H.; Kishida, K.; Komuro, R.; Ouchi, N.; Kihara, S.; Nagai, R.; Funahashi, T.; Matsuzawa, Y. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J. Biol. Chem., 2002, 277, 37487-91.
39. Ouchi, N.; Ohishi, M.; Kihara, S.; Funahashi, T.; Nakamura, T.; Nagaretani, H.; Kumada, M.; Ohashi, K.; Okamoto, Y.; Nishizawa, H.; Kishida, K.; Maeda, N.; Nagasawa, A.; Kobayashi, H.; Hiraoka, H.; Komai, N.; Kaibe, M.; Rakugi, H.; Ogihara, T.; Matsuzawa, Y. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension, 2003, 42, 231-4.
40. Nakamura, Y.; Shimada, K.; Fukuda, D.; Shimada, Y.; Ehara, S.; Hirose, M.; Kataoka, T.; Kamimori, K.; Shimodozono, S.; Kobayashi, Y.; Yoshiyama, M.; Takeuchi, K.; Yoshikawa, J. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart, 2004, 90, 528-33.
41. Kojima, S.; Funahashi, T.; Sakamoto, T.; Miyamoto, S.; Soejima, H.; Hokamaki, J.; Kajiwara, I.; Sugiyama, S.; Yoshimura, M.; Fujimoto, K.; Miyao, Y.; Suefuji, H.; Kitagawa, A.; Ouchi, N.; Kihara, S.; Matsuzawa, Y.; Ogawa, H. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Hear,t 2003, 89, 667.
42. Kojima, S.; Funahashi, T.; Otsuka, F.; Maruyoshi, H.; Yamashita, T.; Kajiwara, I.; Shimomura, H.; Miyao, Y.; Fujimoto, K.; Sugiyama, S.; Sakamoto, T.; Yoshimura, M.; Ogawa, H. Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction. Atherosclerosis, 2006, 194, 204-13.
43. Ohashi, T.; Shibata, R.; Morimoto, T.; Kanashiro, M.; Ishii, H.; Ichimiya, S.; Hiro, T.; Miyauchi, K.; Nakagawa, Y.; Yamagishi, M.; Ozaki, Y.; Kimura, T.; Daida, H.; Murohara, T.; Matsuzaki, M. Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipidlowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study. Atherosclerosis, 2010, 212, 237-42.
44. Shibata, R.; Numaguchi, Y.; Matsushita, K.; Sone, T.; Kubota, R.; Ohashi, T.; Ishii, M.; Kihara, S.; Walsh, K.; Ouchi, N.; Murohara, T. Usefulness of adiponectin to predict myocardial salvage following successful reperfusion in patients with acute myocardial infarction. Am. J. Cardiol., 2008, 101, 1712-5.
45. Shibata, R.; Sato, K.; Pimentel, D. R.; Takemura, Y.; Kihara, S.; Ohashi, K.; Funahashi, T.; Ouchi, N.; Walsh, K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med., 2005, 11, 1096-103.
46. Tao, L.; Gao, E.; Jiao, X.; Yuan, Y.; Li, S.; Christopher, T. A.; Lopez, B. L.; Koch, W.; Chan, L.; Goldstein, B. J.; Ma, X. L. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation, 2007, 115, 1408-16.
47. Shinmura, K.; Tamaki, K.; Saito, K.; Nakano, Y.; Tobe, T.; Bolli, R. Cardioprotective effects of short-term caloric restriction are mediated by adiponectin via activation of AMP-activated protein kinase. Circulation, 2007, 116, 2809-17.
48. Kondo, K.; Shibata, R.; Unno, K.; Shimano, M.; Ishii, M.; Kito, T.; Shintani, S.; Walsh, K.; Ouchi, N.; Murohara, T. Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ. Cardiovasc. Interv., 2010, 3, 166-73.
49. Rutter, M. K.; Parise, H.; Benjamin, E. J.; Levy, D.; Larson, M. G.; Meigs, J. B.; Nesto, R. W.; Wilson, P. W.; Vasan, R. S. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation, 2003, 107, 448-54.
50. Ilercil, A.; Devereux, R. B.; Roman, M. J.; Paranicas, M.; O'Grady M, J.; Welty, T. K.; Robbins, D. C.; Fabsitz, R. R.; Howard, B. V.; Lee, E. T. Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study. Am. Heart. J., 2001, 141, 992-8.
51. Hong, S. J.; Park, C. G.; Seo, H. S.; Oh, D. J.; Ro, Y. M. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood. Press., 2004, 13, 236-42.
52. Ebinc, H.; Ebinc, F. A.; Ozkurt, Z. N.; Dogru, M. T.; Tulmac, M.; Yilmaz, M.; Caglayan, O. Impact of adiponectin on left ventricular mass index in non-complicated obese subjects. Endocr. J., 2008, 55, 523-8.
53. Mitsuhashi, H.; Yatsuya, H.; Tamakoshi, K.; Matsushita, K.; Otsuka, R.; Wada, K.; Sugiura, K.; Takefuji, S.; Hotta, Y.; Kondo, T.; Murohara, T.; Toyoshima, H. Adiponectin level and left ventricular hypertrophy in Japanese men. Hypertension, 2007, 49, 1448-54.
54. Kozakova, M.; Muscelli, E.; Flyvbjerg, A.; Frystyk, J.; Morizzo, C.; Palombo, C.; Ferrannini, E. Adiponectin and left ventricular structure and function in healthy adults. J. Clin. Endocrinol. Metab., 2008, 93, 2811-8.
55. Shibata, R.; Ouchi, N.; Ito, M.; Kihara, S.; Shiojima, I.; Pimentel, D. R.; Kumada, M.; Sato, K.; Schiekofer, S.; Ohashi, K.; Funahashi, T.; Colucci, W. S.; Walsh, K. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med., 2004, 10, 1384-9.
56. Liao, Y.; Takashima, S.; Maeda, N.; Ouchi, N.; Komamura, K.; Shimomura, I.; Hori, M.; Matsuzawa, Y.; Funahashi, T.; Kitakaze, M. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res., 2005, 67, 705-13.
57. Shimano, M.; Ouchi, N.; Shibata, R.; Ohashi, K.; Pimentel, D. R.; Murohara, T.; Walsh, K. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J. Mol. Cell. Cardiol., 2010, 49, 210-20.
58. Fujita, K.; Maeda, N.; Sonoda, M.; Ohashi, K.; Hibuse, T.; Nishizawa, H.; Nishida, M.; Hiuge, A.; Kurata, A.; Kihara, S.; Shimomura, I.; Funahashi, T. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 863-70.
59. Sam, F.; Duhaney, T. A.; Sato, K.; Wilson, R. M.; Ohashi, K.; Sono-Romanelli, S.; Higuchi, A.; De Silva, D. S.; Qin, F.; Walsh, K.; Ouchi, N. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology, 2010, 151, 322-31.
60. Kistorp, C.; Faber, J.; Galatius, S.; Gustafsson, F.; Frystyk, J.; Flyvbjerg, A.; Hildebrandt, P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation, 2005, 112, 1756-62.
61. George, J.; Patal, S.; Wexler, D.; Sharabi, Y.; Peleg, E.; Kamari, Y.; Grossman, E.; Sheps, D.; Keren, G.; Roth, A. Circulating adiponectin concentrations in patients with congestive heart failure. Heart, 2006, 92, 1420-4.
62. Tsutamoto, T.; Tanaka, T.; Sakai, H.; Ishikawa, C.; Fujii, M.; Yamamoto, T.; Horie, M. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur. Heart. J., 2007, 28, 1723-30.
63. Biolo, A.; Shibata, R.; Ouchi, N.; Kihara, S.; Sonoda, M.; Walsh, K.; Sam, F. Determinants of adiponectin levels in patients with chronic systolic heart failure. Am. J. Cardiol., 2010, 105, 1147-52.
64. Ohara, T.; Hashimura, K.; Asakura, M.; Ogai, A.; Amaki, M.; Hasegawa, T.; Kanzaki, H.; Sonoda, M.; Nishizawa, H.; Funahashi, T.; Kitakaze, M. Dynamic changes in plasma total and high molecular weight adiponectin levels in acute heart failure. J. Cardiol., 2011, 58, 181-90.
65. Tsukamoto, O.; Fujita, M.; Kato, M.; Yamazaki, S.; Asano, Y.; Ogai, A.; Okazaki, H.; Asai, M.; Nagamachi, Y.; Maeda, N.; Shintani, Y.; Minamino, T.; Asakura, M.; Kishimoto, I.; Funahashi, T.; Tomoike, H.; Kitakaze, M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J. Am. Coll. Cardiol., 2009, 53, 2070-7.
66. Shibata, R.; Izumiya, Y.; Sato, K.; Papanicolaou, K.; Kihara, S.; Colucci, W. S.; Sam, F.; Ouchi, N.; Walsh, K. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J. Mol. Cell. Cardiol., 2007, 42, 1065-74.
67. Singal, P. K.; Iliskovic, N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med., 1998, 339, 900-5.
68. Maruyama, S.; Shibata, R.; Ohashi, K.; Ohashi, T.; Daida, H.; Walsh, K.; Murohara, T.; Ouchi, N. Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism. J. Biol. Chem., 2011, 286, 32790-800.
69. Konishi, M.; Haraguchi, G.; Ohigashi, H.; Ishihara, T.; Saito, K.; Nakano, Y.; Isobe, M. Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc. Res., 2011, 89, 309-19.
70. de Azambuja, E.; McCaskill-Stevens, W.; Francis, P.; Quinaux, E.; Crown, J. P.; Vicente, M.; Giuliani, R.; Nordenskjold, B.; Gutierez, J.; Andersson, M.; Vila, M. M.; Jakesz, R.; Demol, J.; Dewar, J.; Santoro, A.; Lluch, A.; Olsen, S.; Gelber, R. D.; Di Leo, A.; Piccart-Gebhart, M. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast. Cancer. Res. Treat., 2010, 119, 145-53.
71. Fujioka, D.; Kawabata, K. I.; Saito, Y.; Kobayashi, T.; Nakamura, T.; Kodama, Y.; Takano, H.; Obata, J. E.; Kitta, Y.; Umetani, K.; Kugiyama, K. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am. J. Physiol. Heart. Circ. Physiol., 2006, 290, H2409-16.
72. Pineiro, R.; Iglesias, M. J.; Gallego, R.; Raghay, K.; Eiras, S.; Rubio, J.; Dieguez, C.; Gualillo, O.; Gonzalez-Juanatey, J. R.; Lago, F. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett, 2005, 579, 5163-9.
73. Ikeda, Y.; Ohashi, K.; Shibata, R.; Pimentel, D. R.; Kihara, S.; Ouchi, N.; Walsh, K. Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett, 2008, 582, 1147-50.
74. Holland, W. L.; Miller, R. A.; Wang, Z. V.; Sun, K.; Barth, B. M.; Bui, H. H.; Davis, K. E.; Bikman, B. T.; Halberg, N.; Rutkowski, J. M.; Wade, M. R.; Tenorio, V. M.; Kuo, M. S.; Brozinick, J. T.; Zhang, B. B.; Birnbaum, M. J.; Summers, S. A.; Scherer, P. E. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med., 2011, 17, 55-63.
75. Kobashi, C.; Urakaze, M.; Kishida, M.; Kibayashi, E.; Kobayashi, H.; Kihara, S.; Funahashi, T.; Takata, M.; Temaru, R.; Sato, A.; Yamazaki, K.; Nakamura, N.; Kobayashi, M. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res., 2005, 97, 1245-52.
76. Ouchi, N.; Kihara, S.; Arita, Y.; Okamoto, Y.; Maeda, K.; Kuriyama, H.; Hotta, K.; Nishida, M.; Takahashi, M.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation, 2000, 102, 1296-301.
77. Ouchi, N.; Kobayashi, H.; Kihara, S.; Kumada, M.; Sato, K.; Inoue, T.; Funahashi, T.; Walsh, K. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem., 2004, 279, 1304-9.
78. Kobayashi, H.; Ouchi, N.; Kihara, S.; Walsh, K.; Kumada, M.; Abe, Y.; Funahashi, T.; Matsuzawa, Y. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res., 2004, 94, e27-31.
79. Chen, H.; Montagnani, M.; Funahashi, T.; Shimomura, I.; Quon, M. J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem., 2003, 278, 45021-6.
80. Cheng, K. K.; Lam, K. S.; Wang, Y.; Huang, Y.; Carling, D.; Wu, D.; Wong, C.; Xu, A. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes, 2007, 56, 1387-94.
81. Ohashi, K.; Ouchi, N.; Sato, K.; Higuchi, A.; Ishikawa, T. O.; Herschman, H. R.; Kihara, S.; Walsh, K. Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol. Cell. Biol., 2009, 29, 3487-99.
82. Shibata, R.; Skurk, C.; Ouchi, N.; Galasso, G.; Kondo, K.; Ohashi, T.; Shimano, M.; Kihara, S.; Murohara, T.; Walsh, K. Adiponectin promotes endothelial progenitor cell number and function. FEBS Lett, 2008, 582, 1607-12.
83. Chang, J.; Li, Y.; Huang, Y.; Lam, K. S.; Hoo, R. L.; Wong, W. T.; Cheng, K. K.; Wang, Y.; Vanhoutte, P. M.; Xu, A. Adiponectin prevents diabetic premature senescence of endothelial progenitor cells and promotes endothelial repair by suppressing the p38 MAP kinase/p16INK4A signaling pathway. Diabetes, 2010, 59, 2949-59.
84. Arita, Y.; Kihara, S.; Ouchi, N.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Kumada, M.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Shimomura, I.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 2002, 105, 2893-8.
85. Wang, Y.; Lam, K. S.; Xu, J. Y.; Lu, G.; Xu, L. Y.; Cooper, G. J.; Xu, A. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J. Biol. Chem., 2005, 280, 18341-7.
86. Ouchi, N.; Kihara, S.; Arita, Y.; Nishida, M.; Matsuyama, A.; Okamoto, Y.; Ishigami, M.; Kuriyama, H.; Kishida, K.; Nishizawa, H.; Hotta, K.; Muraguchi, M.; Ohmoto, Y.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation, 2001, 103, 1057-63.
87. Kumada, M.; Kihara, S.; Ouchi, N.; Kobayashi, H.; Okamoto, Y.; Ohashi,K.; Maeda, K.; Nagaretani, H.; Kishida, K.; Maeda, N.; Nagasawa, A.; Funahashi, T.; Matsuzawa, Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation, 2004, 109, 2046-9.
88. Lumeng, C. N.; Bodzin, J. L.; Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest., 2007, 117, 175-84.
89. Ohashi, K.; Parker, J. L.; Ouchi, N.; Higuchi, A.; Vita, J. A.; Gokce, N.; Pedersen, A. A.; Kalthoff, C.; Tullin, S.; Sams, A.; Summer, R.; Walsh, K. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J. Biol. Chem., 2010, 285, 6153-60.
90. Takemura, Y.; Ouchi, N.; Shibata, R.; Aprahamian, T.; Kirber, M. T.; Summer, R. S.; Kihara, S.; Walsh, K. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J. Clin. Invest., 2007, 117, 375-86.
91. Yamauchi, T.; Kamon, J.; Ito, Y.; Tsuchida, A.; Yokomizo, T.; Kita, S.; Sugiyama, T.; Miyagishi, M.; Hara, K.; Tsunoda, M.; Murakami, K.; Ohteki, T.; Uchida, S.; Takekawa, S.; Waki, H.; Tsuno, N. H.; Shibata, Y.; Terauchi, Y.; Froguel, P.; Tobe, K.; Koyasu, S.; Taira, K.; Kitamura, T.; Shimizu, T.; Nagai, R.; Kadowaki, T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 2003, 423, 762-9.
92. Hug, C.; Wang, J.; Ahmad, N. S.; Bogan, J. S.; Tsao, T. S.; Lodish, H. F. Tcadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. U S A., 2004, 101, 10308-13.
93. Denzel, M. S.; Scimia, M. C.; Zumstein, P. M.; Walsh, K.; Ruiz-Lozano, P.; Ranscht, B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J. Clin. Invest., 2010, 120, 4342-52.
94. Tian, L.; Luo, N.; Zhu, X.; Chung, B. H.; Garvey, W. T.; Fu, Y. Adiponectin-AdipoR1/2-APPL1 signaling axis suppresses human foam cell formation: Differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses. Atherosclerosis, 2012, 221, 66-75.
95. Yki-Jarvinen, H. Thiazolidinediones. N. Eng.l J. Med., 2004, 351, 1106-18.
96. Dormandy, J. A.; Charbonnel, B.; Eckland, D. J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I. K.; Skene, A. M.; Tan, M. H.; Lefebvre, P. J.; Murray, G. D.; Standl, E.; Wilcox, R. G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R. J.; Koranyi, L.; Laakso, M.; Mokan, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005, 366, 1279-89.
97. Lincoff, A. M.; Wolski, K.; Nicholls, S. J.; Nissen, S. E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA, 2007, 298, 1180-8.
98. Miyazaki, Y.; Mahankali, A.; Wajcberg, E.; Bajaj, M.; Mandarino, L. J.; DeFronzo, R. A. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab., 2004, 89, 4312-9.
99. Kubota, N.; Terauchi, Y.; Kubota, T.; Kumagai, H.; Itoh, S.; Satoh, H.; Yano, W.; Ogata, H.; Tokuyama, K.; Takamoto, I.; Mineyama, T.; Ishikawa, M.; Moroi, M.; Sugi, K.; Yamauchi, T.; Ueki, K.; Tobe, K.; Noda, T.; Nagai, R.; Kadowaki, T. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J. Biol. Chem., 2006, 281, 8748-55.
100. Horio, T.; Suzuki, M.; Suzuki, K.; Takamisawa, I.; Hiuge, A.; Kamide, K.; Takiuchi, S.; Iwashima, Y.; Kihara, S.; Funahashi, T.; Yoshimasa, Y.; Kawano, Y. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am. J. Hypertens., 2005, 18, 949-57.
101. Asakawa, M.; Takano, H.; Nagai, T.; Uozumi, H.; Hasegawa, H.; Kubota, N.; Saito, T.; Masuda, Y.; Kadowaki, T.; Komuro, I. Peroxisome proliferator- activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation, 2002, 105, 1240-6.
102. Kato, M. F.; Shibata, R.; Obata, K.; Miyachi, M.; Yazawa, H.; Tsuboi, K.; Yamada, T.; Nishizawa, T.; Noda, A.; Cheng, X. W.; Murate, T.; Koike, Y.; Murohara, T.; Yokota, M.; Nagata, K. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J. Hypertens., 2008, 26, 1669-76.
103. Li, P.; Shibata, R.; Unno, K.; Shimano, M.; Furukawa, M.; Ohashi, T.; Cheng, X.; Nagata, K.; Ouchi, N.; Murohara, T. Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone. Hypertension, 2010, 55, 69-75.
104. Higuchi, A.; Ohashi, K.; Shibata, R.; Sono-Romanelli, S.; Walsh, K.; Ouchi, N., Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism. Arterioscler. Thromb. Vasc. Biol., 2010, 30 (1), 46-53.
105. Yamagishi, S.; Nakamura, K.; Matsui, T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator- activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr. Mol. Med., 2007, 7, 463-9.
106. Takagi, H.; Umemoto, T. Telmisartan increases adiponectin levels: A metaanalysis and meta-regression of randomized head-to-head trials. Int. J. Cardiol., 2012. 155, 448-51.
107. Rinaldi, B.; Di Filippo, C.; Capuano, A.; Donniacuo, M.; Sodano, L.; Ferraraccio, F.; Rossi, F.; D'Amico, M. Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in zucker diabetic fatty rats with metabolic syndrome. Diabetes. Obes. Metab., 2012. 14, 320-8.
108. Goyal, S. N.; Bharti, S.; Bhatia, J.; Nag, T. C.; Ray, R.; Arya, D. S. Telmisartan, a dual ARB/partial PPAR-gamma agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes. Obes. Metab., 2011, 13, 533-41.
109. Barter, P. J.; Rye, K. A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler. Thromb. Vasc. Biol., 2008, 28, 39-46.
110. Keech, A.; Simes, R. J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M. R.; Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; Drury, P.; Kesaniemi, Y. A.; Sullivan, D.; Hunt, D.; Colman, P.; d'Emden, M.; Whiting, M.; Ehnholm, C.; Laakso, M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005, 366, 1849-61.
111. Hiuge, A.; Tenenbaum, A.; Maeda, N.; Benderly, M.; Kumada, M.; Fisman, E. Z.; Tanne, D.; Matas, Z.; Hibuse, T.; Fujita, K.; Nishizawa, H.; Adler, Y.; Motro, M.; Kihara, S.; Shimomura, I.; Behar, S.; Funahashi, T. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 635-41.
112. Koh, K. K.; Han, S. H.; Quon, M. J.; Yeal Ahn, J.; Shin, E. K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes. Care., 2005, 28, 1419-24.
113. Rosenson, R. S. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring), 2009, 17, 504-9.
114. Li, P.; Shibata, R.; Maruyama, S.; Kondo, M.; Ohashi, K.; Ouchi, N.; Murohara, T. Fenofibrate promotes ischemia-induced revascularization through adiponectin-dependent pathway. Am. J. Physiol. Endocrinol. Metab., 2010, 299, E560-6.
115. Katayama, A.; Yamamoto, Y.; Tanaka, K.; Matsubara, K.; Sugitani, M.; Fujihara, S.; Harada, S.; Kaetsu, Y.; Yoshida, A.; Hisatome, I. Fenofibrate enhances neovascularization in a murine ischemic hindlimb model. J. Cardiovasc. Pharmacol., 2009, 54, 399-404.
116. Liao, J. K. Clinical implications for statin pleiotropy. Curr. Opin. Lipidol., 2005, 16, 624-9.
117. Nakamura, T.; Kodama, Y.; Takano, H.; Umetani, K.; Fujioka, D.; Saito, Y.; Kawabata, K.; Obata, J. E.; Kitta, Y.; Kobayashi, T.; Mende, A.; Kugiyama, K. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis, 2007, 193, 449-51.
118. Sugiyama, S.; Fukushima, H.; Kugiyama, K.; Maruyoshi, H.; Kojima, S.; Funahashi, T.; Sakamoto, T.; Horibata, Y.; Watanabe, K.; Koga, H.; Sugamura, K.; Otsuka, F.; Shimomura, I.; Ogawa, H. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis, 2007, 194, e43-51.
119. Takagi, T.; Matsuda, M.; Abe, M.; Kobayashi, H.; Fukuhara, A.; Komuro, R.; Kihara, S.; Caslake, M. J.; McMahon, A.; Shepherd, J.; Funahashi, T.; Shimomura, I. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis, 2008, 196, 114-21.
120. Ingram, D. K.; Anson, R. M.; de Cabo, R.; Mamczarz, J.; Zhu, M.; Mattison, J.; Lane, M. A.; Roth, G. S. Development of calorie restriction mimetics as a prolongevity strategy. Ann. N. Y. Acad. Sci., 2004, 1019, 412-23.
121. Kondo, M.; Shibata, R.; Miura, R.; Shimano, M.; Kondo, K.; Li, P.; Ohashi, T.; Kihara, S.; Maeda, N.; Walsh, K.; Ouchi, N.; Murohara, T. Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J. Biol. Chem., 2009, 284, 1718-24.